143 related articles for article (PubMed ID: 38062540)
21. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.
Heimbach T; Kesisoglou F; Novakovic J; Tistaert C; Mueller-Zsigmondy M; Kollipara S; Ahmed T; Mitra A; Suarez-Sharp S
J Pharm Sci; 2021 Dec; 110(12):3896-3906. PubMed ID: 34551349
[TBL] [Abstract][Full Text] [Related]
22. Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions.
Boddu R; Kollipara S; Vijaywargi G; Ahmed T
Xenobiotica; 2023 Apr; 53(4):260-278. PubMed ID: 37471259
[TBL] [Abstract][Full Text] [Related]
23. Approaches to Account for Colon Absorption in Physiologically Based Biopharmaceutics Modeling of Extended-Release Drug Products.
Jadhav H; Augustijns P; Tannergren C
Mol Pharm; 2023 Dec; 20(12):6272-6288. PubMed ID: 37902586
[TBL] [Abstract][Full Text] [Related]
24. Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report.
Pepin X; Arora S; Borges L; Cano-Vega M; Carducci T; Chatterjee P; Chen G; Cristofoletti R; Dallmann A; Delvadia P; Dressman J; Fotaki N; Gray E; Heimbach T; Holte Ø; Kijima S; Kotzagiorgis E; Lennernäs H; Lindahl A; Loebenberg R; Mackie C; Malamatari M; McAllister M; Mitra A; Moody R; Mudie D; Musuamba Tshinanu F; Polli JE; Rege B; Ren X; Rullo G; Scherholz M; Song I; Stillhart C; Suarez-Sharp S; Tannergren C; Tsakalozou E; Veerasingham S; Wagner C; Seo P
Mol Pharm; 2024 Jun; ():. PubMed ID: 38946085
[TBL] [Abstract][Full Text] [Related]
25. Application of physiologically based biopharmaceutics modeling to understand the impact of dissolution differences on in vivo performance of immediate release products: The case of bisoprolol.
Macwan JS; Fraczkiewicz G; Bertolino M; Krüger P; Peters SA
CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):622-632. PubMed ID: 34080804
[TBL] [Abstract][Full Text] [Related]
26. Best Practices in the Development and Validation of Physiologically Based Biopharmaceutics Modeling. A Workshop Summary Report.
Parrott N; Suarez-Sharp S; Kesisoglou F; Pathak SM; Good D; Wagner C; Dallmann A; Mullin J; Patel N; Riedmaier AE; Mitra A; Raines K; Butler J; Kakhi M; Li M; Zhao Y; Tsakalozou E; Flanagan T; Dressman J; Pepin X
J Pharm Sci; 2021 Feb; 110(2):584-593. PubMed ID: 33058891
[TBL] [Abstract][Full Text] [Related]
27. Development of Extended-Release Mini-Tablets Containing Metoprolol Supported by Design of Experiments and Physiologically Based Biopharmaceutics Modeling.
Issa MG; de Souza NV; Jou BWC; Duque MD; Ferraz HG
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631478
[TBL] [Abstract][Full Text] [Related]
28. Prediction of fasted and fed bioequivalence for immediate release drug products using physiologically based biopharmaceutics modeling (PBBM).
Jereb R; Kristl A; Mitra A
Eur J Pharm Sci; 2020 Dec; 155():105554. PubMed ID: 32946959
[TBL] [Abstract][Full Text] [Related]
29. Integrating In Vitro Biopharmaceutics into Physiologically Based Biopharmaceutic Model (PBBM) to Predict Food Effect of BCS IV Zwitterionic Drug (GSK3640254).
Stamatopoulos K; Ferrini P; Nguyen D; Zhang Y; Butler JM; Hall J; Mistry N
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839843
[TBL] [Abstract][Full Text] [Related]
30. Biopharmaceutics Risk Assessment-Connecting Critical Bioavailability Attributes with In Vitro, In Vivo Properties and Physiologically Based Biopharmaceutics Modeling to Enable Generic Regulatory Submissions.
Ahmed T; Kollipara S; Boddu R; Bhattiprolu AK
AAPS J; 2023 Jul; 25(5):77. PubMed ID: 37498474
[TBL] [Abstract][Full Text] [Related]
31. Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report.
Heimbach T; Suarez-Sharp S; Kakhi M; Holmstock N; Olivares-Morales A; Pepin X; Sjögren E; Tsakalozou E; Seo P; Li M; Zhang X; Lin HP; Montague T; Mitra A; Morris D; Patel N; Kesisoglou F
AAPS J; 2019 Feb; 21(2):29. PubMed ID: 30746576
[TBL] [Abstract][Full Text] [Related]
32. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
33. Development of Biopredictive Dissolution Method for Extended-Release Desvenlafaxine Tablets.
Carapeto GV; Duque MD; Issa MG; Ferraz HG
Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242786
[TBL] [Abstract][Full Text] [Related]
34. Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs.
Eckernäs E; Tannergren C
Mol Pharm; 2021 Apr; 18(4):1699-1710. PubMed ID: 33720733
[TBL] [Abstract][Full Text] [Related]
35. Physiologically Based Biopharmaceutics Modeling of Food Effect for Basmisanil: A Retrospective Case Study of the Utility for Formulation Bridging.
Belubbi T; Bassani D; Stillhart C; Parrott N
Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678820
[TBL] [Abstract][Full Text] [Related]
36. Integration of artificial neural network and physiologically based biopharmaceutic models in the development of sustained-release formulations.
Severino Martins F; Borges L; Oliveira do Couto R; Schaller S; de Freitas O
Biopharm Drug Dispos; 2023 Aug; 44(4):335-343. PubMed ID: 37649136
[TBL] [Abstract][Full Text] [Related]
37. Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls: A Workshop Summary Report.
Pepin XJH; Parrott N; Dressman J; Delvadia P; Mitra A; Zhang X; Babiskin A; Kolhatkar V; Suarez-Sharp S
J Pharm Sci; 2021 Feb; 110(2):555-566. PubMed ID: 32380182
[TBL] [Abstract][Full Text] [Related]
38. Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies.
Mitra A; Parrott N; Miller N; Lloyd R; Tistaert C; Heimbach T; Ji Y; Kesisoglou F
J Pharm Sci; 2020 Mar; 109(3):1380-1394. PubMed ID: 31778721
[TBL] [Abstract][Full Text] [Related]
39. Adult and pediatric physiologically-based biopharmaceutics modeling to explain lamotrigine immediate release absorption process.
Caleffi-Marchesini ER; Herling AA; Macente J; Bonan RH; de Freitas Lima P; Moreno R; Alexandre V; Charbe NB; Borghi-Pangoni FB; Cristofoletti R; Diniz A
CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):208-221. PubMed ID: 37916262
[TBL] [Abstract][Full Text] [Related]
40. Mechanistic Models for USP2 Dissolution Apparatus, Including Fluid Hydrodynamics and Sedimentation.
Pepin X; Goetschy M; Abrahmsén-Alami S
J Pharm Sci; 2022 Jan; 111(1):185-196. PubMed ID: 34666045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
